Back to search
FDAFDA · Food and drugs·Recall number D-1276-2019

GlipiZIDE Extended-release Tablets, 2.5 mg, 30 Tablets (3 x 10), Rx Only, Packaged and Distributed by: American Health Packaging, Columbus, Ohio 43217. NDC: 68084-295-21

Published May 8, 2019 · Recall initiated: April 8, 2019

Summary

FDA records drug Class II recall D-1276-2019, published May 8, 2019 and initiated April 8, 2019. Recalling firm: American Health Packaging; Status: Terminated; Reported quantity: 2,203 cartons (cartons of 30 individual unit doses); Lot: Lot # 181288, EXP 5/31/2020. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications: dissolution failure at time zero of the repackaged lot. Drug release results were slightly above specification at time zero.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
American Health Packaging
Distributor
Nationwide in the USA
Lot
Lot # 181288, EXP 5/31/2020
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was GlipiZIDE Extended-release Tablets, 2.5 mg, 30 Tablets (3 x 10), Rx Only, Packaged and Distributed by: American Health Packaging, Columbus, Ohio 43217. NDC: 68084-295-21 recalled?

Yes. FDA published recall D-1276-2019 on May 8, 2019. Reported hazard: Failed Dissolution Specifications: dissolution failure at time zero of the repackaged lot. Drug release results were slightly above specification at time zero.

What should I do if I have this product?

Voluntary: Firm initiated · Letter